Ly6/uPAR-Related Protein C4

Slides:

Advertisements

Similar presentations

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Advertisements

Prognostic Stratification of Stage IIIA pN2 Non-small Cell Lung Cancer by Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data: An.

Overexpression of β-Catenin and Cyclin D1 is Associated with Poor Overall Survival in Patients with Stage IA–IIA Squamous Cell Lung Cancer Irrespective.

Foxp3+ Regulatory T Cells and Natural Killer Cells Distinctly Infiltrate Primary Tumors and Draining Lymph Nodes in Pulmonary Adenocarcinoma Thomas Schneider,

High Expression of PHGDH Predicts Poor Prognosis in Non–Small Cell Lung Cancer Jinhong Zhu, Jianqun Ma, Xudong Wang, Tianjiao Ma, Shu Zhang, Wei Wang,

Non-small Cell Lung Cancer Induces an Immunosuppressive Phenotype of Dendritic Cells in Tumor Microenvironment by Upregulating B7-H3 Thomas Schneider,

A Novel Classification of MUC1 Expression Is Correlated with Tumor Differentiation and Postoperative Prognosis in Non–Small Cell Lung Cancer Shinjiro.

P63 and p73 Isoform Expression in Non-small Cell Lung Cancer and Corresponding Morphological Normal Lung Tissue Marco Lo Iacono, PhD, Valentina Monica,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Tumor marker expression is predictive of survival in patients with esophageal cancer Thomas A Aloia, MD, David H Harpole, MD, Carolyn E Reed, MD, Carmen.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Timon P. H. Buys, BSc, Sarit Aviel-Ronen, MD, Thomas K

Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Non–Small Cell Lung Cancer Mark N. Adams, PhD, Joshua T. Burgess, PhD,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Putative Stem Cell Markers in Non–Small-Cell Lung Cancer: A Clinicopathologic Characterization Willam Sterlacci, MD, Spasenija Savic, MD, Michael Fiegl,

Prognostic Impact of CD204-Positive Macrophages in Lung Squamous Cell Carcinoma: Possible Contribution of Cd204-Positive Macrophages to the Tumor-Promoting.

Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism–related genes Ruben Pio, PharmD, PhD, Jackeline.

Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Charles.

Glucose Metabolism in NSCLC Is Histology-Specific and Diverges the Prognostic Potential of 18FDG-PET for Adenocarcinoma and Squamous Cell Carcinoma Olga.

Prognostic Stratification of Stage IIIA pN2 Non-small Cell Lung Cancer by Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data: An.

Prognostic Impact of Margin Distance and Tumor Spread Through Air Spaces in Limited Resection for Primary Lung Cancer Kyohei Masai, MD, Hiroyuki Sakurai,

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.

Foxp3+ Regulatory T Cells and Natural Killer Cells Distinctly Infiltrate Primary Tumors and Draining Lymph Nodes in Pulmonary Adenocarcinoma Thomas Schneider,

Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage I–II Non–Small-Cell Lung Cancer David J. Stewart, MD, Maria I. Nunez, MD,

Relationship Between Tumor Size and Survival in Non–Small-Cell Lung Cancer (NSCLC): An Analysis of the Surveillance, Epidemiology, and End Results (SEER)

Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer Frank J. Lagerwaard, MD, PhD, Neil K. Aaronson,

Frank Detterbeck, MD Journal of Thoracic Oncology

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Kelsie L. Thu, BSc, Raj Chari, PhD, William W

Telomere Length and Recurrence Risk after Curative Resection in Patients with Early- Stage Non–Small-Cell Lung Cancer: A Prospective Cohort Study Eric.

Non-small Cell Lung Cancer Induces an Immunosuppressive Phenotype of Dendritic Cells in Tumor Microenvironment by Upregulating B7-H3 Thomas Schneider,

Detection of Lung Cancer by Automated Sputum Cytometry

G-Protein Coupled Receptor Family C, Group 5, Member A (gprc5a) Expression Is Decreased in the Adjacent Field and Normal Bronchial Epithelia of Patients.

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer Antonio Calles, MD, Xiaoyun Liao, MD,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Apelin Expression in Human Non-small Cell Lung Cancer: Role in Angiogenesis and Prognosis Judit Berta, MS, Istvan Kenessey, MD, Judit Dobos, PhD, Jozsef.

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

A Pragmatic Approach to the Diagnosis of Nodal Micrometastases in Early Stage Non- small Cell Lung Cancer Esther Herpel, MD, Thomas Muley, PhD, Thomas.

Upregulation of Hypoxia-Inducible Factor-1α mRNA and its Clinical Significance in Non- small Cell Lung Cancer Tomofumi Yohena, MD, Ichiro Yoshino, MD,

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

MiR-205 and MiR-375 MicroRNA Assays to Distinguish Squamous Cell Carcinoma from Adenocarcinoma in Lung Cancer Biopsies Santosh Patnaik, MD, PhD, Reema.

Loss of CRNN expression is associated with advanced tumor stage and poor survival in patients with esophageal squamous cell carcinoma Po-Kuei Hsu, MD,

A Prognostic Model to Predict Mortality among Non–Small-Cell Lung Cancer Patients in the U.S. Military Health System Jie Lin, PhD, MPH, Corey A. Carter,

New IASLC/ATS/ERS Classification and Invasive Tumor Size are Predictive of Disease Recurrence in Stage I Lung Adenocarcinoma Naoki Yanagawa, MD, PhD,

The Prognostic Significance of Focal Adhesion Kinase Expression in Stage I Non– Small-Cell Lung Cancer Grace K. Dy, MD, Lourdes Ylagan, MD, Saraswati.

Angiogenic Markers Show High Prognostic Impact on Survival in Marginally Operable Non-small Cell Lung Cancer Patients Treated with Adjuvant Radiotherapy

Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab

Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer

Prognostic Impact of Node Involvement Pattern in Pulmonary pN1 Squamous Cell Carcinoma Patients Masayuki Nakao, MD, Junji Yoshida, MD, PhD, Genichiro.

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

Use of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non- small Cell Lung Cancer Eric Duncavage, MD, Boone Goodgame, MD, Ananth Sezhiyan,

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Circulating Serum Vascular Endothelial Growth Factor is Not a Prognostic Factor of Non-small Cell Lung Cancer Mohammad Chakra, MD, Jean Louis Pujol,

Volume 372, Issue 9632, Pages (July 2008)

Serum Proteomic Profiling of Lung Cancer in High-Risk Groups and Determination of Clinical Outcomes William Jacot, MD, PhD, Ludovic Lhermitte, MD, Nadège.

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Joan J. Ryoo, MD, MSHS, Jennifer L. Malin, MD, PhD, Diana L

Transcutaneous Computed Bioconductance Measurement in Lung Cancer: A Treatment Enabling Technology Useful for Adjunctive Risk Stratification in the Evaluation.

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation

Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer Murry.

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Neal S Goldstein, MD The Annals of Thoracic Surgery

Influence of Ground Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non–Small Cell Lung Cancer

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Biomarkers in Early-Stage Non–Small-Cell Lung Cancer: Current Concepts and Future Directions Mauricio Burotto, MD, Anish Thomas, MD, Deepa Subramaniam,

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Presentation transcript:

Ly6/uPAR-Related Protein C4 Ly6/uPAR-Related Protein C4.4A as a Marker of Solid Growth Pattern and Poor Prognosis in Lung Adenocarcinoma Benedikte Jacobsen, PhD, Thomas Muley, PhD, Michael Meister, PhD, Hendrik Dienemann, MD, PhD, Ib Jarle Christensen, MSc, Eric Santoni-Rugiu, MD, PhD, Ole Didrik Lærum, MD, PhD, Michael Ploug, PhD Journal of Thoracic Oncology Volume 8, Issue 2, Pages 152-160 (February 2013) DOI: 10.1097/JTO.0b013e318279d503 Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Scoring of C4.4A. A–D illustrate the staining levels in non–small cell lung cancer on which the scoring of C4.4A was based, with intensities gradually increasing from very weak (A), weak (B), moderate (C), to strong (D) (Scale bars: 50 μm). The correlation between C4.4A scores at the tumor center and periphery is presented as scatter plots for AC and SCC in E and F, respectively. G and H depict box plots of center and periphery scores of C4.4A, delimiting the values for upper and lower quartiles, as divided by pathological stage I–IV (AC to the left and SCC to the right). The median is shown as a line within each box, and the dots represent outliers. AC, adenocarcinoma; SCC, squamous cell carcinoma. Journal of Thoracic Oncology 2013 8, 152-160DOI: (10.1097/JTO.0b013e318279d503) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 C4.4A provides prognostic information in adenocarcinoma but not squamous cell carcinoma patients. Correlation of C4.4A scores with survival of adenocarcinoma and squamous cell carcinoma patients is illustrated by Kaplan–Meier estimates (tumor center score) in A and B, respectively, grouped by their respective tertiles (in red, blue, and green). The number of events (death of all causes), patients at risk at 0, 24, 48, and 72 months, and range of C4.4A scores are indicated below the axis for each tertile. Journal of Thoracic Oncology 2013 8, 152-160DOI: (10.1097/JTO.0b013e318279d503) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 C4.4A is primarily expressed in the solid component of pulmonary adenocarcinomas. Specimens of pulmonary adenocarcinoma were stained with our polyclonal anti-C4.4A antibody and developed with NovaRED chromogen. As shown in the examples of solid, acinar, and papillary growth patterns in A, B, and C, respectively, most C4.4A reactivity is found in solid components. Scale bars: 100 μm. Journal of Thoracic Oncology 2013 8, 152-160DOI: (10.1097/JTO.0b013e318279d503) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions